Thyroid Cancer therapy with I-131. Malignant neoplasms of thyroid and other endocrine glands
Conditions
Interventions
Intervention 1: Intervention group:Using oral Pilocarpine every 8 hours, start at 2 hours after administration of radioiodine. Intervention 2: Control group:Using oral Placebo every 8 hours, start at
Prevention
Intervention group:Using oral Pilocarpine every 8 hours, start at 2 hours after administration of radioiodine.
Control group:Using oral Placebo every 8 hours, start at 2 hours after administration of radioiodine.
Sponsors
Shiraz university of medical science, Vice chancellor for research
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients with diagnosis of hyperthyroidism or thyroid cancer who are candidate for radioiodine therapy Exclusion criteria: patient with history of uncontrolled asthma; bronchospasm; severe COPD; heart failure; acute iritis; close angle glaucoma; pateint use antihypertensive drugs; history of salivary gland disease; no patient consent.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Organ dose per administered I131 Activity (ODPA). Timepoint: 1,2,3,4,5,13,25,48 h after receiving radio-iodine 131. Method of measurement: By scintigraphy and MIRD Schema software calculations. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects of radio-Iodine 131. Timepoint: Every 4-6 weeks. Method of measurement: Asking the patient. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNuclear medicine and molecular imaging research center
Shiraz university of medical science
Outcome results
None listed